Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
EUPRAXIA PHARMACEUTICALS INC.
Conservative balance sheet (liabilities/equity 0.07x).
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
EUPRAXIA PHARMACEUTICALS INC. shows $0.00 in FY2025 revenue, and -47.0% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001581178, latest 6-K filed 2026-05-29) · EODHD · rules-based read · as of 6/18/2026, 1:08:35 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | -$18.5M | -$28.2M | -$25.5M | -$38.6M |
| Diluted EPS | -$0.96 | -$1.17 | -$0.76 | -$1.03 |
| Net margin | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
501 tracked peers · median